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ABSTRACT 
The employment of the stable isotope labeling with amino acids in cell culture (SILAC) based proteomic analysis as a guidance tool 
for investigation of cellular response of a multifunctional nanodelivery system has been described for cancer therapy. The 
multifunctional nanodelivery system in this study was based on an estrogen anchored multimodal nanomicelle (NPG). The key 
components of the multifunctional nanomicelle consist: β-cyclodextrin conjugated estrone (CDE1), an escort molecule; polymeric 
BH3 mimetic, a proapoptotic BcL-2 inhibitor; and the mitotic catastrophe agent paclitaxel. They were assembled into the 
nanomicelle by multiple weak interactions including hydrophobic/hydrophilic interaction and host-guest recognition. The resulting 
nanomicelle exhibited unimodal morphology with average size of 170 nm with sustained release. It was found that the nanoparticle 
exhibits excellent anti-tumor activities for the treatment of breast adenocarcinoma with exceptional targeting efficacy both in MCF-7 
tumor bearing mice. NPG as a new drug delivery system demonstrated several merits such as the increased drug uptake in breast 
tumor tissue, low toxicity, potent tumor growth retardation and metastasis inhibition, as well as potential clinical practicality without 
compromising liver, kidney and immune function and ameliorating the conventional chemotherapeutics induced phlebitis in breast 
tumor bearing nude mice model. The systematic SILAC based proteomics study and the subsequent validation revealed that the 
synergistic induction of mitotic catastrophe through enhanced G2/M phase arrest and PI3K/Akt/mTOR mediated autophagy, account 
for the exceedingly potent anti-tumor activity of this convergent nanomicelle. Additionally, the verification of the top upregulated 
gene from the proteomics profiling revealed that the overexpression of zinc finger protein 350 (ZNF350/ZBRK1) is associated with 
the enhanced antitumor effect induced by NPG. 
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INTRODUCTION 
The heterogeneity and instability of cancer genomes 
results in highly variable clinical outcomes for cancer 
treatment.
1
 In current clinical practice, combination 
regimens are routinely applied although the scientific 
evidence for the combination therapies is weak. In a 
hope of improving the clinical outcome of the 
combination regimens, combined modality therapy in a 
nanoformulation in terms of multifunctional 
nanomedicine has attracted increasing attention and 
provides a promising direction for cancer therapy.
2
 
Multifunctional nanomedicines integrate comprehensive 
functionalities with different mechanisms of drug action, 
providing targeted, ratiometric delivery of drugs or 
genes, consequently making significant improvement of 
their pharmacokinetic/dynamic profile compared to the 
conventional nanomedicines.
3-6
 However, application of 
the majority of multifunctional nanodelivery systems are 
substantially hampered due to their inherent complexity 
in vivo, including the heterogeneities of tumor vascular 
permeability,
7
 varying pharmacokinetics, nonspecific 
biodistributions, and unpredicted adverse effects. One 
critical reason for the limitations is the lack of 
understanding of the sophisticated drug actions amongst 
the multiple constituents in the integrated nanoparticles 
for the treatment of cancer. 
 
 
Figure 1: Schematic of the novel nanoparticle. Above is a schematic representation of nanoparticles developed in this 
study. Targeted multifunctional Nanoparticles formulated by functionalized PEG-PLA and synergetic 
chemotherapeutics, for improved anticancer activity. The various modifications to the PEG-PLA polymer allow the 
nanoparticle to be capable of targeted co-delivery of therapeutics. (PEG-PLA: copolymers of polyethylene glycol and 
polylactic acid; CD: cyclodextrin; AD: Adamantyl group) 
 
Previous approaches for assessing drug synergy in 
multifunctional nanoparticles were usually empirical 
which always suffered from the low accuracy and 
uncertain predictability.
6
 No doubt, the accurate 
information of proteome wide cellular response 
triggered by the multifunctional nanoparticle from 
proteomics would provide a key to understanding the 
molecular mechanism underlying the anti-tumor effects 
from the multiagents interactions in the highly 
convergent nanoparticles, and consequently facilitate the 
development of new generation nanotherapeutics for 
cancer. Proteomics reveals large-scale information of 
proteomes and uncovers important points in the cell 
signaling from complex mixtures; and they have 
attracted increasing attention in drug discovery.
8-9
 
SILAC based proteomics, which relies on the 
incorporation of amino acids with substituted stable 
isotopic nuclei and enables data interpretation and 
quantification more accurate and robust, has emerged as 
a powerful approach in pharmaceutical sciencej. 
However, the proteomics has never been demonstrated 
in the investigation of the multifunctional nanoparticle 
triggered cellular pathways for cancer therapy.
10-11
 
Proteomics facilitated analysis of cellular trafficking 
induced by nanoparticles would be particularly attractive 
because it could reveal the mechanic paradigms of the 
anti-tumor effects from a complex high convergent 
nanoparticle, consequently, facilitating the development 
of new drugs for treatment of cancers . We expect that 
the marriage of SILAC based proteomics and 
multifunctional nanoparticle would open an 
unprecedented door for cancer research. 
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Herein, we present the first example of the cancer 
therapeutic study for the combinational therapeutics in 
targeting nanomicelles as drug delivery systems guided 
by proteomics. The judicious design and synthesis of a 
multifunctional polymer micelle which incorporates 
functionalities including membrane estrogen receptor 
(mER) targeting, mitotic catastrophe inducing, and BcL-
2/Bcl-xL inhibiting for mER (+) breast adenocarcinoma 
is depicted in Figure 1. In addition to the evaluation of 
the antitumor effect in vitro and in vivo, the molecular 
mechanism behind the therapeutic outcome was 
investigated by systematic epigenetic study and SILAC 
based proteomes mining. The top molecules and top 
pathways in the response of the nanoparticle NPG were 
analyzed. The anti-tumor potency of NPG results from 
synergistically enhanced mitotic G2/M phase arrest and 
autophagy instead of the expected apoptosis. The 
validation of the top gene from the proteomics profiling 
revealed that the upregulation of ZNF350 is associated 
with the enhanced antitumor effect of NPG and 
represents a potential therapeutic target induced by the 
nanoparticles. 
RESULTS AND DISCUSSION 
Design, Synthesis and Characterization of the 
Multifunctional Nanoparticle  
The selection of an appropriate ligand for a nanoparticle 
is critical to ensure its precise and exclusive tumor 
targeting for the designed nanoparticle based on 
different types of cancers.  To initiate our proteomic 
directed cancer therapeutic study of multifunctional 
nanoparticles, mER(+) breast cancer was utilized as a 
model to test our concept. Thus estrogen was selected as 
a targeting vector since mERs on the breast cancer cell 
membrane such as classic ERα, ERα splicing variants 




 GPR30, and Gαq-
mER
16
 could bind by estrogens. On the other hand, the 
dual drugs functioned in different mechanisms such as 
the anti-mitotic agent paclitaxel (PTX)
17
 and a BH3 
mimetic gossypol (Gsp)
18
 were encapsulated in the 
nanoparticle. With these key elements synthesized, we 
fabricate a multifunctional nanodrug delivery system 
through host-guest recognition between cyclodextrins 
and adamantyl groups based on our previous established 
approaches 
19
 and hydrophobic drug interaction 
triggered self assembling. 
20
 
In particular, the estrone anchored multifunctional 
nanomicelles (NPG) consists of five components as 
shown in Figure 1 and Scheme S1 in Supp Info. They 
are: anti-mitotic agent paclitaxel (PTX), which was 
encapsulated in the inner core of NPG; natural BH3 
mimetic, a racemic Gsp with low aqueous solubility as 
adjuvant drug conjugated to the terminal of the di-block 
polymer to form the hydrophilic G-PEG-PLA; CDE1 as 
the targeting moiety; adamantane attached polymer AD-
PEG-PLA as linker of CDE1 to the nanoparticle; PEG-
PLA as the base material in NPG. 
The synthetic procedure for the NPG was convergent 
and straightforward. First, CDE1 was readily 
synthesized from estrone and amino-β-cyclodextrin19 
through Borch reduction as a targeting moiety. The 
polymer linker AD-PEG-PLA was prepared by an 
amidation reaction of the corresponding commercially 
available admantyl carbonyl chloride and the terminal 
amine derived PEG-PLA. The drug G-PEG-PLA was 
installed through the formation of imine functionality 
from the gossypol and amino-PEG. Through the well-
known host-guest interactions of admantyl group and 
the cyclodextrin functionality, the conjugate of CDE1 
and AD-PEG-PLA was readily formed. After all the 
components functionalized, the final multifunctional 
nanoparticle (NPG) was fabricated by a hydrophobic 
drug-triggered self-assembly and host-guest recognition 
with overall hydrophilic property. The structure of, the 
resultant nanoparticle and the corresponding 
intermediates were fully characterized by nuclear 
magnet resonance (NMR), mass spectrometry (MS), 
fourier transform infrared spectroscopy (FTIR) and 
liquid chromatography (LC) as shown in Figure S1-3.  
To determine the morphology, particle size distribution 
and surface zeta-potential of the resulting 
multifunctional NPG, a variety of techniques such as 
scanning electron microscopy (SEM), transmission 
electron microscopy (TEM) and dynamic light 
scattering (DLS) were carried out. The NPG shows a 
unimodal and narrower size distribution of 18%. The 
SEM image in Fig 2A showed spherical particles with 
an average diameter of approximately 170 nm. The size 
was twice that of the starting material PEG-PLA (Fig 
S7), indicating the geometrical fabrication of the 
nanoparticle. TEM microscopic images of NPG 
displayed an obvious morphology change compared to 
that of the starting polymer, again indicating the 
occurrence of the self-aggregation. Additionally, the 
TEM image clearly showed that the nanoparticle 
consists of multiple small spherical domains. The small 
domains were around 170 nm according to the statistical 
analysis of three samples, supporting that the small 
domains were conventional micelles self-assembled 
from the subunits. In addition, the surface charge of the 
NPG was investigated by DLS, and the results were 
consistent TEM and SEM, in addition, it showed that the 
ζ-potential value is 5.8 mV, suggesting thermodynamic 
and kinetic stability of the nanoparticle. Thus, the as-
prepared nanoparticles were formed through a self-
assembly by host-guest recognition and hydrophilic 
interactions. 
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Figure 2: Transmission electron microscopic and scanning electron microscopic observations of the multi-functional 
polymeric micelles (A) SEM images of NPG (65K); (B-D) TEM images of NPG, samples were prepared from the 
MCF-7 cells after NPG exposure for 5 min; B: The NPG nanoparticles have been observed line alone the cell 
membrane (10k); C: Endocytosis of the nanoparticle (80k); D: Vesicles (as arrows shown) migrate actively to the cell 
membrane to internalize the nanoparticle (150k). (E) Samples were prepared from the MCF-7 cells after NPG exposure 
for 10 min, vesicles break apart as the arrow shown (40K). (F-I) Samples were prepared from the MCF-7 cells after 
NPG exposure for 15 min; F: Nanoparticles are shown inside the cells, some of the nanoparticles have been digested, 
leave the empty out shell (as the arrow shown); G: NPG (with averaged diameter of 170 nm) are clearly shown the 
outer shell and inner core with drug encapsulated (40k); H: One enlarged nanoparticle of NPG; I: The encapsulated 
drug released and dispersed inside the MCF-7 cells as the arrow shows. 
Moreover, the morphology of the nanoparticle in MCF-
7 cancer cell was investigated by TEM. TEM images in 
tissue also showed the structure of the nanoparticle with 
the diameter of average 170 nm outer shell and inner 
core with drug encapsulated. Importantly, excellent cell 
permeability and drug release capability of the 
multifunctional nanoparticle was observed. As shown in 
Fig 2F, the TEM image showed that there were quite a 
few nanoparticles inside the cells, while some of the 
nanoparticles had been digested and left the out shell 
alone. Notably, at 15 min after the nanoparticles were 
internalized into the tumor cells, the typical and delicate 
two-phase micelle structure with outer hydrophilic 
layers and inner hydrophobic cores has been clearly 
observed (Figure 2F-H),  the enlarged one polymeric 
micelle is shown in Figure 2H, which also demonstrate 
the successful preparation. The encapsulated drug was 
released and dispersed inside the MCF-7 cancer cells as 
shown in Fig 2I. These results demonstrated the 
promising prerequisite of the resulting multifunctional 
nanoparticles in treatment of cancer.  
Additionally, the NPG demonstrated excellent 
ratiometric drugs release capability and low cytotoxicity 
compared to the parent drugs. For instance, the drug 
release from the nanoparticle significantly lags behind 
the parent drug, its release was continuous and sustained 
up to 16.8% for the nanoparticle with kd value of 20.38 
vs 83.9% for the encapsulated fluorescent probe with kd 
=0.4 after 56 h, the drug in the nanoparticle was 
abruptly dissociated within 0.5 h and then slightly 
release while the parent drug has a sharp rise at 8 and 24 
h with relative drug release percentage of 17.8% and 
51.9% respectively (Figure S5). As for the cytotoxic 
assays, NPG shows a significantly lowered IC50 value 
(1.9 nM) than the corresponding nontargeting 
nanopaticle NPC (3.9 nM). Additionally, the 
progressively declined cytotoxicity response and the 
long-term drug release of the NPG were more 
predominant up to 72 h compared with PTX due to the 
stability of the NPG. 
Moreover, the NPG showed the most potent tumor 
sphere inhibition compared to blank, Gsp, G-PEG-PLA, 
NPC, and PTX groups as demonstrated in the ex vivo 
tumor colony inhibition study (Figure S10). For 
example, when the tumor colonies were exposed to the 
drugs for 48 h, the tumor colony at the NPG treated 
group exhibited a 44.0% decrease in size, while only 
8.34% in G-PEG-PLA treated group and 18.43% for 
PTX treated group.  
The membrane receptor mediated endocytosis procedure 
during the internalization of NPG by mER (+) breast 
cancer cells has been proposed due to the targeting 
function of CDE1 interpolated in NPG and verified 
based on the findings. Firstly, TEM was used to capture 
the process at increasing time periods after exposure to 
NPG at 50 nM in MCF-7 cells. NPG can only be 
observed lined up along the cell membrane at the 5 min 
time point after the treatment with NPG (Figure 2B, S7), 
such tight junctions between the nanoparticles and the 
tumor cell membrane indicates that NPG bonds with 
plasma membrane protein(s) or certain receptor(s), 
otherwise the physical association between NPG and 
cell surface would be disrupted and rinsed off by the 
following procedure before fixation. The caveolae-like 
pit with a nanoparticle can be observed on the cell 
membrane in Figure 2C. During the internalization, the 
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newly formed round and small vesicles migrate actively 
to the cytoplasma membrane for the uptake of the 
nanoparticles as the arrows show in Figure 2D. At a 
later time point of 10 min, endosomal vesicles have 
been observed to disperse and release the nanoparticle 
drug after internalization as arrows show in Figure 2E. 
These results provide evidence for the membrane 
receptor mediated endocytosis for NPG uptake which 
took place in a quick process. Cristae of mitochondria 
and other healthy organelles can be observed (Figure 
S7) indicating the undamaged cell stage within short 
drug exposure time. The delicate microstructure of the 
released drugs and empty polymer shells from the 
polymer micelles have been captured during the drug 
release and digestion which give a clear picture for the 
dynamic process during the internalization, drug release 
and digestion of NPG by the tumor cells. Secondly, to 
further confirm the interaction of NPG with mER, flow 
cytometry analysis was performed in MCF-7 cells. The 
compound Ada-DOX
19
 with intrinsic fluorescence was 
encapsulated in the estrogen anchored nanoparticles 
instead of PTX as same equivalent (Figure S19). Figure 
S19A shows representative quantitative flow cytometric 
results of the cellular uptake of the estrogen anchored 
nanopaticles (T) and non-targeting nanoparticles (N) 
without estrogen moiety attached. Within 18 h of drug 
exposure, estrogen anchored nanoparticles uptake by 
MCF-7 cells has shown a tendency to increase over non-
targeting nanoparticles, and considerably augmented 
uptakes by 11.8% and 34.6% observed at time point of 
24 and 48 h compared with non-targeting nanoparticles, 
which indicates that mER facilitate the uptake of the 
targeting nanoparticles over the nanoparticle without the 
estrogen ligands attached. At last, we performed the 
competition assay with NPG using the synthetic ER 
ligand analog ethinyl estradiol (EE) and selective ER 
modulator tamoxifen (TAM) in MCF-7 cells. The 
results (Figure S19B) showed that both EE and TAM at 
0.1 and 1 μM inhibited NPG uptake in a concentration 
independent manner in MCF-7 cells. EE and TAM 
diminished the uptake of nanoparticles by 25.7% (1M 
EE), 20.0% (0.1M EE), 14.1% (1M TAM) and 20.7% 
(0.1M TAM) respectively in MCF-7 cells (***P < 
0.001). Based on the findings, the mER mediated 
endocytosis of NPG internalization has been confirmed. 
SILAC Based Proteomic Quantification Analysis  
Initial results have shown that the multifunctional NPG 
exhibited excellent tumor cell growth inhibition, and 
sustained drugs release through receptor mediated 
endocytosis. In order to gain comprehensive mechanic 
information for understanding of cell response triggered 
by NPG in breast carcinoma cells, a systematic 
proteomic study of NPG was conducted. 
 
Figure 3 Top canonical pathways (A) and top toxicity pathways (B) enriched in the proteome of multifunctional nano-
particles NPG treated breast cancer cells generated using IPA software. Orange dots indicate ratio, ratio was calculated 
by dividing the number of genes from our dataset that map to each single pathway by the total number of genes 
included into the canonical and toxicity pathways. Blue bars denote –log (P-value) by right-tailed Fisher’s Exact test, 
indicating the statistical significance of the molecules in each criterion. Ratio and –log (P-value) are indicated on the 
left and right side of the histogram, respectively. 
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Specifically, stable isotope labeling with amino acids in 
cell culture (SILAC) based quantitative proteomic 
analysis has been performed, the entire proteome of drug 
treated MCF-7 cells is metabolically labeled by heavy, 
non-radioactive isotopic variants of amino acids equally 
combined with unlabeled samples thus making it 
distinguishable by nanoLC-MS/MS analysis. Cell 
lysates were prepared right after drug treatment of NPG, 
Gsp, G-PEG-PLA, NPC and PTX on MCF-7 cells for 12 
h at 50 nM, and then the cell lysates were proteolytically 
digested and desalted. The protein expression altered in 
MCF-7 breast cancer cells treated with NPG compared 
with its constituents: PTX, Gsp, G-PEG-PLA and NPC. 
We obtained a data set of 138 pro teins for NPG, 315 
proteins for Gsp, 294 proteins for G-PEG-PLA, 495 
proteins for NPC and 301 proteins for PTX (Addendum 
I) after filtering the proteins that showed a significant 
similarity(Pearson’s correlation >0.2). 
Top canonical pathways and top toxicity pathways 
enriched in the proteome of NPG treated breast cancer 
cells generated using the Ingenuity Pathway Analysis 
(IPA) software are given in Figure 3. The key pathway 
network of NPG response in MCF-7 cells 
algorithmically generated based on their functional and 
biological connectivity, is graphically represented in 
Figure 4. 
 
Figure 4: Relationships between highest scored regulated pathways trigger by NPG from the SILAC proteomics in 
MCF-7 cells analyzed by IPA, algorithmically generated based on their functional and biological connectivity, was 
graphically represented as boxes (pathways) and lines (the biological relationship between the pathways).  
 
The most signiﬁcant canonic pathways seen are the cell 
cycle of G2/M,  DNA damage checkpoint regulation 
signaling, PI3K/AKT signaling, Myc mediated 
apoptosis, mTOR  signaling, ERK5 signaling, 
telomerase extension signaling constitute the majority of 
pathways highlighted in the drug response induced by 
NPG. The cell cycle of G2/M DNA damage checkpoint 
regulation signaling and G1/S checkpoint regulation 
signaling pathways are indicated to play critical roles for 
the cytotoxicity in response to the drug NPG. Moreover, 
in the analysis of upstream regulators, it shows the 
predicted activation of β-estrodiol relate to the NPG 
stimulating pathway which reflects the estrogen-like 
activity of CDE1 (Figure S11 and Addendum II).  In the 
IPA functional analysis, the protein identifications of top 
up regulated and down regulated molecules and their 
fold-change expression with respect to NPG treated 
MCF-7 breast cancer cells are shown in Table 1. 
Notably, among the top genes (or proteins) up regulated 
and down regulated based on the IPA network analysis, 
ZNF350  appears to be the most outstanding up 
regulated gene with 15 fold change unique to NPG 
group which is absent in Gsp, G-PEG-PLA, NPC and 
PTX treated groups. In the disease and biofunction 
examination of proliferation for tumor cell lines (Figure 
S12), the essential role of ZNF350 is annotated for the 
MCF-7 cells after NPG treatment. Upregulation of 
ZNF350 is confirmed after NPG treatment in MCF-7 
bearing nude mice and will be discussed. ZNF350 
protein has been reported to decreases malignant 
growth of Hela cells in cell culture and nude mice, and 
acts as a metastatic suppressor by directly regulating 
MMP9 in cervical cancer.
21 
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Table 1 Ingenuity Pathway Analysis (IPA) functional analysis. Annotations for the top ten up- and down-regulated 
genes are indicated  
 
The interaction of ZNF350 with MMP9, BRCA1
22
 and 
microRNAs are also predicted to be a network based on 
evidence in literature which is shown in Figure S13. The 
proteomics profiling provided valuable information on 
mechanism and target druggability that will accelerate 
the downstream drug development,
23-24
 furthermore, 
allowing us to achieve precise design and 
implementation for nanomedicines.  
Validation of the Cytotoxic Pathways and the Top 
Regulated Gene in Vitro and in Vivo from Proteomic 
Annotation  
Annotated by the proteomics studies, we further 
validated the major pathways for the proteomics 
profiling such as G2/M check point regulation, G1/S 
check point regulation for cell cycle, apoptosis signaling, 
PI3k/AKT/mTOR mediated autophagy signaling, and 
Erk/MAPK signaling annotated in Figure 3 and 4. 
Firstly, the time course effect of the nano-formulations 
on cell cycle progression was examined to validatethe 
key network of NPG response in MCF-7 cells (Figure 5 
and S15-17). Treatment of the MCF-7 cells with NPG at 
concentrations of 50 nM led to a significant increase in 
the G2/M population over the 2, 4, 8, 12, 24, 48 and 72 h 
time periods in comparison to PTX, followed by an 
increased fraction of the sub-G1 population and 
appearance of tetraploidy. The G2/M population 
percentage after NPG treatment for 12 h is 77.6%, 
71.03% and 44.80% for NPC and PTX. Increasing the 
length of drug treatment to 72 h did not further 
contribute to the G2/M population increase. Overall, 
NPG caused the most enhanced G2/M accumulation in 
MCF-7 cells and the effect sustained for the longest 
observed time period. NPC shows less effect on cell 
population change of cell cycle than NPG, while more 
potent than PTX.  In regards to Gsp and G-PEG-PLA 
treated groups, a slight increase for G2/M phase was 
recorded after 12 h but then change back and became 
comparable to the control groups for all G1, S, and 
G2/M phase population. In the investigation of cell cycle 
associated proteins by time course western blot (WB) for 
2 to 72 h drug treatments, the G2/M phase checkpoint 
regulation though the p53 dependent and p21
WAF1/CIP1
 
associated CDK1/Cyclin B1 inhibition pathway was 
shown to be the predominate mechanism to induce 
tumor cell death induced by NPG. Additionally, MCF-7 
cells underwent morphological changes from a 
polygonal appearance to rounded shape in response to 
NPG, NPC and PTX treatments at 50 nM for 12 h, NPG 
and NPC caused more cells damage compared with 
PTX, while the cells have no obvious morphological 
difference after the Gsp and G-PEG-PLA treatment at 50 
nM for 12 h (Figure 5D).   
Moreover, mTOR signaling is within the top ten 
pathways indicated in the proteomics profile about 
MCF-7 breast cancer cells response after NPG 
treatment. The time course of NPG preferentially 
induces mTOR dependent autophagy in MCF-7 cells and 
in MCF-7 tumor bearing nude mice, was monitored by 
flow cytometry, WB and confocal microscopy (Figure 6 
and S18). Autophagosome vacuole formation and 
protein light chain 3 (LC3I/II) upregulation were 
observed, which have been further proved in animal 
tumor model by TEM, immunohisto chemistry (IHC) 
and WB (Figure S29-31). Figure 5 shows flow 
cytometry analysis of autophagic flux in MCF-7 cells 
after drug exposure with NPG, Gsp, G-PEG-PLA, NPC 
and PTX at 50 nM for 12 and 24 h. Notably, NPG 
induced the formation of autophagic vesicles and 
autophagosomes more significantly than Gsp, G-PEG-
PLA, and NPC compared with the control groups, there 
is no significant change for parent PTX. Autophagy 
induced by NPG occurred within hours and was 
sustained up to 48 h, a longer time period than those 
witnessed in Gsp, G-PEG-PLA, and NPC. Within the 
first two hours, there showed 11.8 % autophagic 
vacuoles and autophagic flux for NPG treated cells 
compared with 4.1% in Ctrl groups, the groups averaged 
11.9, 12.7, 11.2 and 5.5% for Gsp, G-PEG-PLA, NPC, 
PTX respectively, after drug exposure for 12 and 24 h, at 
48 h, most of the cells are in the late stage. 
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Figure 5: (A-C) FACS analysis of cell cycle distribution of MCF-7 cells after treatment with varying formulated of 
nanoparticles at 50 nM for 4, 12 and 24 h Values of SD were less than 5%.The histogram depicting the percentage of 
cells G1, S, G2/M, sub G1 phase; (D) The cellular morphology of the MCF-7 cells after the drug exposure under 
inverted phase microscope. 
It has been reported that PTX causes inhibition of 
autophagy in breast cancer cells, both by decreasing 
autophagosome formation and by altering 
autophagosome trafficking and localization.
25
 Effective 
autophagy enhancement was observed in MCF-7 cells 
indicating that NPG stimulates cell death in the 
appropriate context. NPG induced robust autophagy 
while paclitaxel released from the micelles blocked a 
latter step in the pathway and autophagic flux by 
confocal microscopy. Autophagic vacuole accumulation 
and flux are both detected by Cyto-ID® Autophagy 
Green dye as observed after induction with NPG, Gsp, 
G-PEG-PLA, NPC and PTX for 12 h at 37°C. White 
arrows indicate the characteristic punctate pattern of 
autophagosome, which occurs upon autophagic 
induction. leading to an accumulation of 
autophagosomes prior to induction of apoptosis though 
their effect on autophagy trafficking, resulting in 
eventual cell death, which suggested that manipulation 
of autophagy of nanotherapeutics may represent a 
therapeutic approach for improving breast cancer 
treatment options. It has been well demonstrated that 
autophagy depends on Atg5/Atg7,
26
 which is associated 
with microtubule-associated LC3I/II truncation and 
lipidation, NPG increased LC3 level by 22.9% and 
32.2% for LC3I and LC3II separately at 8 h, and 8.1% 
and 24% at 12 h, and the autophagosome number in 
MCF-7 cells suggesting that the components in NPG act 
synergistically to induce autophagy-related cell death in 
breast cancer cells. Additionally, TEM microimages of 
MCF-7 cells induced by NPG were captured at early to 
late stage autophagy. (Figure 7, S7) The typical 
autophagic features of cells were observed after 
treatment with NPG, whereas untreated cells had normal 
nuclear and cytoplasmic morphology based on   the 
TEM measurement. The initiation, elongation, closure, 
maturation and degradation stages involved in the 
autophagy process have been successfully captured 
separately. The control groups are shown in Figure 7A, 
without the induction of the drug, the cells are dormant 
and in an inactive state, clear nuclei and cytoplasma 
have been observed. The very initial step of autophagy 
is presented in Figure 7B, the surrounding and 
sequestering of cytoplasmic organelles and proteins 
within an isolation membrane, termed phagophore was 
observed with typical horse-shoe shape (as the red arrow 
shows). The nascent membranes are fused at their edges 
to form double-membrane vesicle-autophagosomes (as 
purple arrows show). Autophagosomes undergo a 
stepwise maturation process, including docking and 
fusion with acidiﬁed endosomal and/or lysosomal 
vesicles (as orange arrows show) eventually leading to 
the delivery of cytoplasmic contents to lysosomal 
components, where they fuse, then degrade. 
Furthermore, the time course of upstream regulated 
proteins associated with autophagy has also been 
examined (Figure S18). The treatment for NPG caused 
the down regulation of Akt and phosphorylated PI3K at 
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Tyr199 by 35.6% and 32.2%. Importantly, the 
downstream-phosphorylated mTOR at Ser248 revealed 
a 28.2% decrease. Inhibition of the upstream event such 
as mTOR phosphorylation and PI3k/Akt 
phosphorylation has been detected along with LC3II 
generation.  Additionally, Beclin-1, also known as the 
autophagy-related gene, was up-regulated by 19.1% 
within 8 h in the time course study and reduced by 
27.1% subsequently at the 24 h time point, it is most 
abundant at 24 h for the PTX group. A 29.6% decline in 
phosphorylated AMPKα at Th172 was also observed. 
Moreover, significantly increased expression levels of 
Erk1 (p42 MAPK) and phosphorylation at Th202 (p-p42 
MAPK) have also been recorded which are factors that 
contribute to autophagy stimulated by NPG. For NPG, 
G-PEG-PLA, NPC and PTX treated groups, p42 MAPK 
expression level shows 84.1%, 19.8%, 42.3%, 32.5% 
increases in comparison to the control groups 
respectively, and phosphorylated p42 MAPK increases 
by 111.2%, 221.8%, 249.7%, 222.7% respectively. 
While Gsp treated groups show comparable amounts of 
Erk1/2 stimulation to the control groups.  
 
Figure 6: NPG induces autophagy in MCF-7 cells. (A) Western blot was used to detect the expression of LC3I/II. Cells 
were treated with 50 nM NPG, G, G-PEG-PLA, NPC and PTX at 50 nM for 12 h. (B) Quantitative analysis of 
expression of LC3I/II based on WB.  (C) Flow cytometry analysis of autophagic flux in MCF-7 cells detected by Cyto-
ID® Autophagy Green dye incubated with NPG, G, G-PEG-PLA, NPC and PTX at 50 nM for 12, and 24 h. (D) 
Visualization of autophagic accumulation and autophagic flux by confocal microscopy. Autophagic vacuole 
accumulation and flux are both detected by Cyto-ID® Autophagyy Green dye as observed after induction with NPG, 
Gsp, G-PEG-PLA, NPC and PTX for 12 h at 37°C. White arrows indicate the characteristic punctate pattern of 
autophagosome, which occurs upon autophagic induction. 
Yin et al                                                                                                                   Journal of Drug Delivery & Therapeutics. 2018; 8(2):41-53                     
ISSN: 2250-1177                                                                               [50]                                                                              CODEN (USA): JDDTAO 
 
Figure 7: Electron microscopic analysis of autophagy in progressive stages. (A): Control samples without drug 
treatment. (B-I): NPG were incubated for 12 h at 50 nM. The cells were then fixed and processed for electron 
microscopy. B: Representative electron micrographs showing horseshoe shaped early stage of autophagy-phagophore 
(red arrow); C-D: Active lysosome (Orange arrows) which engulfs micro vesicles and vesicles; E-F: Representative 
graphs showing close contact of autophagosome (Purple arrows) with lysosome right before docking and fusion of 
autophagosome with lysosome; H-I: Selected micrographs showing the autolysosome and late stage of autophagy, the 
coalition of autolysosomes and lamella structure formed (Yellow arrows).   
In regards to PTEN, there is no significant change 
observed for all the drug tested groups. The results 
proved that PI3k/Akt/mTOR and ERK1/2 signaling 
pathways involved autophagic activity is another major 
cause of cell death besides mitotic arrest and augments 
the action of the encapsulated PTX. At the same time, 
few apoptotic nuclei from the TEM images have been 
observed unexpectedly. Moreover, according to the 
detection of the less than 5% apoptotic cell population 
shown in Figure S20-S21, it has been concluded that 
apoptotic activities induced by NPG play a minor role in 
tumor cell death. 
In Vivo Therapeutic Studies in Nude Mice Guide by 
Proteomics Investigation 
Finally, the anti-tumor activity has been evaluated in 
vivo. Athymic nude mice were implanted subcutaneously 
with MCF cells. When the animals developed palpable 
tumors after 10 days, they were treated intravenously 
with NPG and PTX with equal equivalent (2.36 mg 
PTX/kg body weight in a total volume of 100 μL) once a 
week for sequential 5 weeks. Animals in the control 
group received intravenous administration (i. v.) of 
saline. In vivo drug distribution within 48 h are shown in 
Figure 8 in which NPG treated group were injected with 
the NPG containing 98% PTX and 2% PTX-oregon 
green 488 conjugate, and PTX treated group using 98% 
PTX and 2% PTX-oregon green 488 conjugate PTX 
mixture. Mice in the NPG treated group display 
dramatically elevated drug uptake in tumor xenograft 
tissue as compared to Mice of the PTX group which 
shows nonspecific drug distribution. In addition, the 
drug excretion though urine was recorded and made 
detectable through red fluorescence in mice bladders. 
NPG shows double extended circulation half life time. 
The first fluorescent urine was recorded at 6 h for the 
mice in PTX group, while it was at 12 h after the NPG 
administration. Tumor growth curve, mice body weight 
change, representative images of gross MCF-7 cell 
tumors and tumor metastasis detection from dissected 
organs from the nude mice treated with either control or 
PTX and NPG respectively are shown in Figure 9. Mice 
in the control group developed rapidly growing 
subcutaneous tumors. After five injections, the average 
tumor volumes in Ctrl, PTX and NPG treatment groups 
were 3883.58, 1868.57 and 1084.93 mm
3
 respectively. 
Remarkably, animals in the NPG group exhibited 
significantly retarded tumor development compared to 
the animals in the control group (*p<0.05), and shows 
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Figure 8 In vivo drug distributions of NPG and PTX in MCF-7 tumor-bearing mice. The NPG was encapsulated with 
98% PTX and 2% PTX-Oregon Green 488 Conjugate; PTX groups use 98% PTX and 2% PTX-Oregon Green 488 
conjugate. The drug was injected i. v. into MCF-7 cells xenograft nude mice. (A) Imaging of mice at 6, 12, 24, and 48 h 
after injection for NPG group. (B) Imaging of mice at 6, 12, 24, and 48 h after injection for PTX group. (Exposure 
time=1s, Ex=465 nm, Em=520 nm)  
 
Figure 9: Antitumor effect of NPG nanoparticle in the breast tumor xenografts. (A) The growth curve of MCF-7 
xenografts showed that NPG significantly inhibited the growth of tumor as compared with the control (*p= 0.028), and 
retard tumor development more potent than PTX group. (B) The body weights of the mice in all groups (C) Typical 
photos of mice on day 35. After five injections, the average tumor volumes in Ctrl, PTX and NPG treatment groups 
were 3883.58, 1868.57, 1084.93 mm3 respectively. (D) Representative GFP fluorescence images of organs dissected 
from control, PTX and NPG-treated mice to evaluate the tumor metastasis. The organs are presented as lung, brain, 
heart, liver, spleen and kidney in an order from left to the right and from top to the bottom.  
 
The body weight of the mice in the NPG, PTX and 
control group shows no significant change. Liver 
metastasis was detected though bio-fluorescence 
imaging of the dissected organs from the nude mice 
injected with GFP transfected MCF-7 tumor cells 
(Figure 9D, Figure S24). Blue circles indicate the tumor 
metastasis nodules, and the fluorescence intensity was 
quantitated by the IVIS spectrum. It revealed that NPG 
treatment inhibited liver metastasis from breast tumors 
as well as PTX with the tumor metastasis inhibition rate 
of 77.83% and 70.71% respectively according to the 
quantitation of photointensity of the GFP expression 
site. Notably, NPG markedly alleviated the vein injury 
traditionally caused by PTX as shown in Figure S25, 
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hematoxylin and eosin (H&E) stained micrographs of 
the blood vessel of the mice tail vein from PTX treated 
group showed deformed and narrow vein compared with 
veins the normal morphology after NPG treatment. The 
vasculature photographs revealed that the vessels of the 
mice in PTX group are dilated, tortuous, and hyper-
permeable, in contrast, the vascular architecture 
maintained clear, orderly characteristics for the vascular 
walls in the NPG treated mice which indicated practical 
importance for potential clinic implementation.  
The whole blood hematologic and serum biochemical 
variables were also evaluated for the mice (Figure S26). 
The complete blood count (CBC) revealed a slightly 
decreased leukocytes density for the NPG group.  
Importantly, high platelet counts from the control group, 
considered to be one indicator of cancer, was 
ameliorated to normal reference range for 100% of the 
mice in the NPG treated group, in comparison to 40% of 
the PTX group.  Hematology serum biochemistry 
parameters show that the serum blood urea nitrogen 
(BUN) and creatinine level in the control mice was 19.0 
mg/dL (20.0-26.0 mg/dL for the normal range) and 0.3 
mg/dL (0.5-1.6 mg/dL) in average which is lower than 
the normal range, the serum BUN and creatinine levels 
in the NPG treated mice were varied within 20.9 to 24.0 
mg/dL which is elevated to the normal range standard 
reference. There is no remarkable change for the serum 
levels of alanine amino transferase (ALT) and alkaline 
phosphatase (ALP) in all of the mice.  
 
Figure 10: Summary of the validated pathway induced 
by NPG 
Furthermore, flow cytometric assay of drug-mediated 
immune response in peripheral-blood cells of the mice 
was conducted (Figure S27). The cells were 
subsequently permeabilized and stained with cell-
surface markers. The lymphocytes including CD19 (+) 
B cell and CD49b (+) Natural Killer (NK) cells in blood 
were not significantly affected.  
WB and immunohistochemistry (IHC) analysis in vivo 
revealed upregulated autophagy indicator-LC3 
expression levels in NPG treated mice in comparison to 
the control mice.   
The H&E stained and the TEM microimages from the 
tumor sections of the mice treated by the nanoparticles 
NPG, PTX and saline are shown in Figure S28 and S29, 
catastrophic cytoplasmic vacuolization has been 
observed in the tumor tissue of the nanoparticle treated 
mice more obviously than the other group due to the 
proposed autophagy caused by NPG.  
The proteomics annotation of NPG response in breast 
cancer cells reveals that the ZNF350 are stimulated 
during treatment, WB and IHC analysis in vivo 
confirmed the proteomic data demonstrating that the top 
gene ZNF350 (or ZBRK1) was significantly more 
abundant in NPG treated mice than in the control and 
PTX group (Figure S30,31). ZNF350 is considered as 
valuable anti-oncogene for NPG anti-tumor activity in 
breast cancer. Importantly, activation of ZNF350 is 
absent in the annotation from the proteomics profiling 
for all other single constitutes formulated in the 
nanoparticle as Gsp, polymeric gossypol and PTX. It 
revealed that ZNF 350 is stimulated uniquely by the 
integrated drug interaction formulated in the 
nanoparticles other than the single drug regime. 
Meanwhile the drug synergism in NPG enhanced the 
overall therapeutic effect. Therefore our data strengthen 
the conclusion that ZNF350 may acts as an 
oncosuppressor in the presence of NPG, revealing 
ZNF350 to be as a promising therapeutic gene from the 
antitumor study in vitro and in vivo based on the finding 
from nanoparticulated drugs. The summary of the 
validated pathway induced by NPG is shown in Figure 
10. NPG causes comprehensive intracellular signal 
transduction after the mER facilitated drug 
internalization and digestion (Supp Info). NPG induces 
breast tumor cell death though mitotic catastrophe with 
synergism from PTX, and induces unexpected 
autophagy resulting from the combinational composites 
of NPG which is distinct from the single drug actions.  
CONCLUSIONS 
In summary, we successfully synthesized a novel 
estrogen anchored multifunctional polymeric 
nanoparticle NPG for the codelivery of a mitotic agent 
paclitaxel and a BH3 mimic gossypol which shows 
advantages over the conventional paclitaxel formulation 
in vitro and in vivo. The drug mechanism was 
investigated assisted by systematic SILAC based 
proteomic study. The NPG treatment in vivo showed 
improved drug hydrophilicity to avoid the solvent 
associated side effect of Taxol in clinical use, targeted 
tumor accumulation, increased drug uptake, extended 
circulation time in vivo, significant metastasis inhibition, 
enhanced anti-tumor therapeutic efficacy, protection 
from vein injury due to intravenous administration, and 
negligible damage to kidney, liver function as well as 
immune system at given dosage. Systematic proteomics 
study and validation in vitro and in vivo for drug 
response of NPG in breast cancer revealed that 
synergistically enhanced G2/M phase arrest, 
PI3K/Akt/mTOR and Erk1/2 mediated autophagy 
mainly contribute to the mechanism of cancer cell death, 
instead of the expected inhibition of pro-apoptotic BcL-
2 from gossypol besides the mitotic catastrophe 
resulting from paclitaxel which shows that 
multifunctional nanoparticles stimulate unique cellular 
response and  results in new mechanisms compared with 
single drug regimes. NPG is evident as a promising drug 
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candidate for clinical translation to treat mER (+) 
tumors. Proteomics data and the validation suggest that 
the upregulation of ZNF350 induced by the 
combinational NPG may be associated with the anti-
tumor efficacy against breast cancer in vivo, thereby 
ZNF350 as a new therapeutic target reveals the 
treatment paradigms for the combinational therapeutic 
nanoparticles and it is worthwhile for further 
investigation. In a word, utilization of proteomics for the 
investigation of mechanic pathways triggered by 
multifunctional nanoparticles for cancer therapy 
provides critical insight in nanodrug development and 
their therapeutic targets. 
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